CDKN2A is a member of the family of cyclin-dependent kinase inhibitor genes and may be involved in the development of EMT and infiltration of immune cells through regulating LIPH expression.[28] Besides, it had been widely reported that CDKN2A was related to the poor prognosis of various cancers, including hepatocellular carcinoma, gliomas and colorectal cancer.[29–31] Both SCD and SNAI1 are recognized oncogenes in multiple cancer types. This evidence concerns the gene CDKN2A and central nervous system cancer.